skip to content


Issue No. 27 | November 18, 2016

News and Features

FDA Approves New Formulations of Maraviroc and Approves Maraviroc for Pediatric Use

On November 4, 2016, the Food and Drug Administration (FDA) approved three new formulations of maraviroc (brand name: Selzentry): 20 mg/mL oral solution, 25 mg tablets, and 75 mg tablets.

FDA also approved the use of maraviroc in pediatric patients 2 years of age and older weighing at least 10 kg.

The updated label is available at the FDA website.

More information is available:

Adult and Adolescent Opportunistic Infections Guidelines Updated

The Coccidioidomycosis section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was rewritten to update recommendations for various types of coccidioidomycosis. It emphasizes that in HIV-infected persons with CD4 counts >250/µL, coccidioidomycosis can be managed in the same manner as in those without HIV infection. The triazole antifungals fluconazole and itraconazole remain the mainstays of treatment. Antiretroviral therapy in patients with coccidioidomycosis should not be delayed because of concern for immune response inflammatory syndrome.

December 1 is World AIDS Day

According to the Centers for Disease Control and Prevention (CDC), worldwide about 36.7 million people are living with HIV. CDC further reports that as of June 2016, 17 million people—less than half of the world’s population of people with HIV—were receiving antiretroviral therapy (ART).

World AIDS Day is an occasion to celebrate and support ongoing global efforts to provide ART to all people with HIV and to one day make new HIV infections and deaths due to AIDS something rare. To learn more, browse our World AIDS Day webpage [en español].

Recent HIV/AIDS News from NIAID